Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 7, 2026
Reporting Period: As of July 7, 2026
Business Context: The Company is an emerging growth company focused on the development of tafenoquine for the treatment of severe babesiosis. This filing discloses the preparation of a statistical analysis plan (SAP) for an interim analysis of its ongoing randomized, placebo-controlled trial (NCT0627370).
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Progress
- Statistical Analysis Plan (SAP): The Company prepared an SAP for the interim analysis of its severe babesiosis trial. The analysis is scheduled for the earlier of October 30, 2026, or after 24 of the 33 planned patients have been randomized and followed for at least 50 days.
- Interim Analysis Criteria:
- If conditional power (CP) is at least 80%, a log-rank test will be performed. A one-sided statistical significance of 0.02137 or less for time to sustained clinical resolution (TTSCR) will result in early reporting.
- If CP is between 50% and 80% for TTSCR or time to molecular cure (TTMC), a sample size reassessment will occur, capped at an increase of 33 additional patients (66 total).
- Enrollment Status: As of the filing date, 23 patients have been enrolled in the study.
- Regulatory Strategy: The Company intends to apply for a Commissioner's National Priority Review Voucher if the trial outcomes support a supplementary New Drug Application (sNDA) submission before the end of Q1 2028.
Guidance, Outlook, and Risks
Outlook: Management anticipates submitting an sNDA and a Priority Review Voucher application contingent on positive interim or final analysis results, with a target timeline for sNDA submission before Q1 2028.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks associated with clinical development outcomes, interactions with regulatory authorities (FDA), and market conditions. The Company assumes no obligation to update these statements.
Key Facts for Investor Verification
- Verify the current enrollment count (23 patients) against the interim analysis trigger (24 patients followed for 50 days).
- Monitor the timeline for the interim analysis (targeted for October 30, 2026, or upon meeting patient criteria).
- Confirm the specific statistical thresholds (80% conditional power, 0.02137 significance level) required for early study reporting.
- Track the feasibility of the Q1 2028 sNDA submission and the subsequent Priority Review Voucher application.